Description
Besifloxacin is a fourth generation fluoroquinolone antibiotic that displays broad-spectrum antibacterial activity against aerobic and anaerobic bacteria and is effective against a wide range of ocular pathogens that exhibit resistance to other fluoroquinolone antibiotics. Besifloxacin inhibits DNA topoisomerase IV and DNA gyrase, preventing DNA replication, transcription, and repair. This compound also inhibits production of IL-1Ra, IL-6, IL-1-β, MCP-1, and other pro-inflammatory cytokines; it may also inhibit NF-kB signaling.
References
Miller D, Chang JS, Flynn HW, et al. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci. J Ocul Pharmacol Ther. 2013 Apr;29(3):339-44. PMID: 23289847.
Lan W, Petznick A, Heryati S, et al. Nuclear Factor-κB: central regulator in ocular surface inflammation and diseases. Ocul Surf. 2012 Jul;10(3):137-48. PMID: 22814642.
Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009 Mar;63(3):443-50. PMID: 19147516.
Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008 Jan;61(1):111-6. PMID: 17965029.
